The effect of mixed-function oxidase and amine oxidase inhibitors on the activation of dialkylnitrosamines and 1,2-dimethylhydrazine to bacterial mutagens in mice.
The effect of the mixed-function oxidase inhibitor phenylimidazole (PI) and the amine oxidase inhibitors iproniazid (IPRO) and aminoacetonitrile (AAN) on the mutagenic activity of various carcinogens was determined in intrasanguineous host-mediated assays, using mice as hosts and E. coli 343/113 as an indicator of mutagenic activity. The carcinogenic compounds dimethyl-, diethyl-, methylethyl-, and diethanolnitrosamine (DMNA, DENA, MENA, and DELNA respectively) and 1,2-dimethylhydrazine (SDMH) were administered i.p. to mice pretreated or not with one of the inhibitors. After 4 h exposure to each of the carcinogens, E. coli cells recovered from the liver of non-pretreated mice showed considerable induction of VALr mutations; after pretreatment of the hosts with the three inhibitors, significant reduction of the amounts of induced mutants in vivo was observed. Particularly, PI proved a very efficient inhibitor of DENA, MENA, DELNA, and SDMH mutagenicity (93%-97% reduction), suggesting that these carcinogens are mainly activated by cytochrome P-450-dependent enzymes. However, since PI might also inhibit the NAD-mediated activation of DELNA by alcohol dehydrogenase (ADH), the present experiments do not rule out an additional role of ADH in the in vivo mutagenic activation of DELNA. AAN and IPRO were less and much less effective, respectively, in reducing the mutagenic activity of all compounds. Surprisingly, PI showed less inhibition of the mutagenic activity of DMNA (60% reduction), as compared to the other carcinogens; this indicates that metabolic routes other than the cytochrome P-450-dependent enzyme system may be important for the activation of DMNA.
D019813:1,2-Dimethylhydrazine; D006631:Amine Oxidase (Copper-Containing); D000607:Aminoacetonitrile / Q000494:pharmacology; D000818:Animals; D001711:Biotransformation; D004127:Dimethylhydrazines / Q000378:metabolism*; D004128:Dimethylnitrosamine / Q000378:metabolism; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D007093:Imidazoles / Q000494:pharmacology; D007490:Iproniazid / Q000494:pharmacology; D008763:Methylhydrazines / Q000378:metabolism*; D051379:Mice; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors*; D009153:Mutagens / Q000378:metabolism*; D009602:Nitrosamines / Q000378:metabolism*; D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000037:antagonists & inhibitors*
D004127:Dimethylhydrazines; D007093:Imidazoles; D008763:Methylhydrazines; D009153:Mutagens; D009602:Nitrosamines; D000607:Aminoacetonitrile; C037738:1-phenylimidazole; D007490:Iproniazid; D006899:Mixed Function Oxygenases; D006631:Amine Oxidase (Copper-Containing); D000587:Oxidoreductases Acting on CH-NH Group Donors; D019813:1,2-Dimethylhydrazine; D004128:Dimethylnitrosamine